Lundbeck begins Phase II DARE2 trial for Parkinson's drug Lu AF28996

H. Lundbeck A/S has begun the Phase II DARE2 placebo-controlled trial for its oral dopamine agonist prodrug Lu AF28996 in advanced Parkinson's disease, following positive Phase Ib results. The drug showed tolerable side effects and signs of improved motor control.